- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Wellness reports Rs 105.34 crore net loss in Q2
New Delhi: Zydus Wellness on Monday reported widening of its consolidated net loss to Rs 105.34 crore for the quarter ended on September 30, 2020, from that of Rs 12.02 crore in the year-ago period. Total income stood at Rs 344.80 crore for the reported quarter, up 4.49 percent compared to Rs 329.98 crore for the same period a year ago, Zydus Wellness said in a BSE filing.
During the quarter under review, Zydus Wellness reported exceptional expenses of Rs 97.95 crore against Rs 10.05 crore in the same period a year ago. "In the process of integration and concluding the merger of the acquired entity, the company incurred various expenses towards transition service agreement (TSA), consultancy fees, stamp duties, legal and professional charges and other incidental charges.
"The company would not have incurred these expenses in the normal course of business and hence these expenses are classified as exceptional items for the quarter and six months ended September 30, 2019, and year ended March 31, 2020," the company said.
Zydus Wellness said the secured non-convertible debentures (NCDs) that were previously issued by the company have been purchased by its subsidiary company from the market aggregating to Rs 1,10,500 lakh during the quarter ending September 30, 2020 and are held by the subsidiary company as of September 30, 2020. Exceptional expenses also includes the premium amount paid towards purchase of the non-convertible debentures by its subsidiary company.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751